EDITORIAL
Editorials represent the opinions
of the authors and JAMA and
not those of the American Medical Association.
Impugning the Integrity of Medical Science
The Adverse Effects of Industry Influence
Catherine D. DeAngelis, MD, MPH
Phil B. Fontanarosa, MD, MBA
T
HE PROFESSION OF MEDICINE, IN EVERY ASPECT—
clinical, education, and research—has been inundated with profound influence from the pharmaceutical and medical device industries. This has
occurred because physicians have allowed it to happen, and
it is time to stop.
Two articles1,2 in this issue of JAMA provide a glimpse of
one company’s apparent misrepresentation of research data
and its manipulation of clinical research articles and clinical
reviews; such information and articles influence the education and clinical practice of physicians and other health professionals. The direct influence of for-profit companies on education3-6 and clinical practice7,8 has been well documented, so
this Editorial deals primarily with clinical research.
The articles by Ross and colleagues1 and by Psaty and Kronmal2 document how one company, Merck & Co Inc, apparently
manipulated dozens of publications to promote one of its products. But make no mistake—the manipulation of study results,
authors, editors, and reviewers is not the sole purview of one
company.9-12 In this case, documents that provided evidence
necessary to demonstrate the manipulation became public (and
publishable) because of litigation involving one of that company’s products, rofecoxib. As disclosed in the articles,1,2 all authors, except one, report having served as paid consultants for
plaintiffs in litigation against Merck. However, at our insistence
the authors of both studies have made all documents used in
their articles available on the Internet and have provided the
information necessary to access those documents (ie, Web site
addresses) in the articles. Thus, anyone questioning the veracity or interpretation of the information in these 2 articles,1,2 or
wishing to inspect the documents referenced in these 2 articles,
will have ready access to the materials.
The study by Ross et al1 illustrates that clinical trial articles
and review articles related to rofecoxib frequently were written by unacknowledged authors who were employees of forprofit information industries, and often attributed first (or primary) authorship to academically affiliated investigators who
either had little to do with the study or review or who did not
disclose financial support from the company. It is important
to note that for some of the referenced publications listed in the
Table of the article by Ross et al,1 some of the authors either did
not actually receive financial support from the company; were
not required by the journal in which the study was published
to disclose their financial support or relationship with the sponsor; did report their financial support or relationship with the
sponsor, but the journal chose not to publish those author disclosures; or did disclose their financial support, and those disclosures were published.
However, it is clear that at least some of the authors played
little direct roles in the study or review, yet still allowed themselves to be named as authors. Individuals, particularly physicians, who allow themselves to be used in this way, especially
for financial gain, manifest a behavior that is unprofessional and
demeaning to the medical profession and to scientific research.
The study by Psaty and Kronmal,2 which is based on analysis of published articles, information provided by the company to the US Food and Drug Administration (FDA), and
the company’s own internal analysis, shows how Merck may
have misrepresented the risk-benefit profile of rofecoxib in clinical trials involving patients with Alzheimer disease or dementia. The authors show that the company’s report to the FDA
appears to have attempted to minimize the mortality risk by
using an “as-treated” analysis, whereas an internal analysis conducted by the company several months earlier and using the
correct intention-to-treat analysis provided evidence of a significantly increased mortality risk among patients assigned to
receive rofecoxib. The authors also report that, for at least 1
rofecoxib trial, company documents reveal that there had been
no data and safety monitoring board in place, thereby potentially endangering patients who participated in this study. Moreover, as Ross et al1 describe in their evaluation of this same
trial (Figure 2 in their article), the data analysis for this study
may have been completed before the academically affiliated
authors were involved with the manuscript; this may not be
surprising, given that 8 of the 11 authors named in the byline
of the published article are identified as being Merck employees.
Journal editors also bear some of the responsibility for enabling companies to manipulate publications. Some editors
may allow articles and supplements to be published without
requiring complete disclosure of individual financial support, and without requiring clear and complete disclosure of
industry support of and direct involvement with research arAuthor Affiliations: Dr DeAngelis is Editor in Chief (cathy.deangelis@jama-archives
.org) and Dr Fontanarosa is Executive Deputy Editor, JAMA.
See also pp 1800 and 1813.
©2008 American Medical Association. All rights reserved.
(Reprinted) JAMA, April 16, 2008—Vol 299, No. 15
Downloaded from www.jama.com on April 15, 2008
1833
EDITORIAL
ticles or reviews. But even when disclosure is required and
closely monitored, manipulation can still occur. For example, Figure 3 in Ross et al1 includes a cover letter (dated
October 2000) from Scientific Therapeutics Information Inc
for the delivery of a manuscript “ . . . to be submitted to JAMA
Express.” The study was, indeed, published in JAMA (in January 2002),13 but not as an Express article. In that publication,
it was disclosed that Merck sponsored the trial; that 3 of the 5
authors (including the first and corresponding author) were
employees of Merck; and that the other 2 authors (who were
identified as the coprincipal investigators) disclosed receiving funding from Merck. However, there was no disclosure
that the manuscript had been written by Scientific Therapeutics Information Inc, a company specializing in the development of scientific literature,14 ie, writing papers for a price.
Perhaps some editors, investigators, reviewers, and readers would see little or no harm in this failed disclosure because all other disclosures were made. However, if there was
nothing to hide, why were the names (and affiliations) of
the individuals who actually wrote at least the first draft of
the manuscript omitted? Experienced authors know that the
initial draft (in this case paid for by Merck) sets the tone
for the manuscript. Moreover, it is unfair to the authors of
the first draft not to provide them with credit for their
work.15,16 Another problem with failing to disclose “ghost
writers” is that there is a reasonable assumption that the principal investigator was involved with writing the manuscript from the beginning. If a professional (ghost) writer
is listed as an author, the issue becomes determining when
the principal investigator became involved in the study. Even
with the requirement for registering clinical trials,17 identifying the principal investigator is not one of the required
elements in the registration information fields. It might be
advantageous for including the names of the principal investigator(s) to become a requirement in trial registration,
even though the vast majority of medical journals do not
require registration of clinical trials.
It can be argued that merely disclosing relationships with
for-profit companies and identifying who actually writes articles for publication does little to stop the practices for cases
in which the relationships are unethical or in which the sponsor has inappropriate influence over the data or control over
the manuscript . However, disclosure does provide readers with
information that can be used in deciding about the credibility of the article—at least as interpreted by the reader. Full
disclosure also might prove too embarrassing to authors who
might reconsider lending their name and reputations to articles in which they did not meet requirements for authorship.
The article by Psaty and Kronmal2 also represents another example of problems with data misrepresentation, data
analysis, and selective reporting in industry-sponsored studies.9,18 In an effort to counteract such problems, in 2001 JAMA
began to require that for all studies, an academic investigator who is not employed by the sponsor must attest that he
or she “had full access to all of the data in the study and
1834 JAMA, April 16, 2008—Vol 299, No. 15 (Reprinted)
takes responsibility for the integrity of the data and the accuracy of the data analysis.”19 In addition, for studies that
are financially supported by for-profit companies, JAMA began to require that the data analysis must be conducted independently by an academic statistician who is not an employee of the sponsor and who is at an academic center, such
as a medical school, or is an employee of a government research institute.19 This approach provides an additional layer
of oversight for the integrity of the data analysis and reporting, such that if concerns about data manipulation or misrepresentation arise, a mechanism for investigation would
be in place, such as by investigative committees appointed
by the dean of the academic medical center at which the independent statistician is a faculty member. If all journals
would have similar policies,20 the likelihood of manipulation of data, inappropriate data analysis, and selective reporting of results could be substantially decreased.
Another source that may contribute to the manipulation of
research studies involves peer reviewers who have relationships with industry. Such reviewers may provide biased reviews that favor products of companies with which they have
strong financial relationships, may fail to disclose their conflicts of interest to journal editors, or may even provide forprofit companies with confidential information obtained during the peer review process. For example, it was recently
reported that a peer reviewer for the New England Journal of
Medicine sent a confidential manuscript that he was invited
to review and that demonstrated an increased mortality risk
associated with rosiglitazone to the manufacturer of this drug
weeks ahead of the publication.21 Even though most journals
require reviewers to disclose potential conflicts of interest, and
editors must consider those disclosures in authorizing reviewers to complete reviews, actions such as this constitute a breach
of trust and a violation of the ethical principles and confidentiality on which the peer review process is based.
What are the lessons from the 2 articles1,2 in this issue of
JAMA, from other publications that have examined related issues,11,12 and from extensive experience with how clinical research has been manipulated by for-profit companies? First,
manipulation of studies and misrepresentation of study results could not occur without the cooperation (active and tacit)
of clinical researchers, other authors, journal editors, peer reviewers, and the FDA. Second, public trust for clinical research is in great jeopardy especially when the extent of how
widespread such practices have become is unknown. Although we truly believe that the vast majority of researchers
and other authors are honest and have the highest scientific
integrity, manipulation of studies and publications by the pharmaceutical and medical device industries is either increasing
or there has been more exposure of these practices. Third, in
addition to clinical research, clinical practice and medical education also are greatly influenced by for-profit companies. Drastic action is essential, and cooperation of everyone involved
in medical research, medical editing, medical education, and
clinical practice is required for meaningful change to occur.
©2008 American Medical Association. All rights reserved.
Downloaded from www.jama.com on April 15, 2008
EDITORIAL
As a beginning, we propose the following:
1. All clinical trials must be prospectively listed in registries accepted by the International Committee of Medical Journal Editors (ICMJE) prior to patient enrollment, and the
name(s) of the principal investigator(s) should be included
as a required data element in the trial registration record.
2. All individuals named as authors on articles must fulfill authorship criteria. Journals should require each author to report his or her specific contributions to the article, and should consider publishing these contributions.
All individuals who were involved with the manuscript or
study but who do not qualify for authorship (such as those
who provided writing assistance) must be named in the acknowledgment section of the article, with reporting of their
specific affiliations and contributions and whether they were
compensated for those contributions.
3. All journals must disclose all pertinent relationships
of all authors with any for-profit companies, and must publish all funding sources for each article.
4. Journal editors must seriously consider funding sources
andauthors’disclosedfinancialconflictsofinterestandfinancial
relationshipswhendecidingwhethertopublishastudyorreview.
5. For-profit companies that sponsor biomedical research studies should not be solely or primarily involved in
collecting and monitoring of data, in conducting the data
analysis, and in preparing the manuscript reporting study
results. These responsibilities should primarily or solely be
performed by academic investigators who are not employed by the company sponsoring the research.
6. All journals must require a statistical analysis of clinical trial data conducted by a statistician who is not an employee of a for-profit company.
7. Any author who fails to disclose financial relationships or other conflicts of interest, or who allows his or her
name to be used for work that he or she did not actually
perform, must be reported to the appropriate authority (ie,
medical school dean or department chair) or appropriate
oversight body. If an article in which this occurs is published, the offending author must then submit a letter to the
editor, in which he or she provides full disclosure and apologizes for the infraction to the readers of the journal. Depending on the nature and severity of the issue, the author
may be banned from publishing articles in that journal.
8. Any peer reviewer who provides any confidential information, such as a manuscript under review, to any third
parties, such as for-profit companies, or who engages in other
similar unethical behavior, also should be reported to the
appropriate authority (eg, medical school dean) or oversight body, and should be banned from reviewing and publishing articles in that journal.
9. Any editor who knowingly allows (or is party to allowing) for-profit companies to manipulate his or her journal must be relieved of the editorship.
10. To maintain a healthy distance from industry influence, professional organizations and providers of continu©2008 American Medical Association. All rights reserved.
ing medical education courses should not condone or tolerate for-profit companies having any input into the content
of educational materials or providing funding or sponsorship for medical education programs.
11. Individual physicians must be free of financial influences of pharmaceutical and medical device companies including serving on speaker’s bureaus or accepting gifts.
Primum non nocere does not only hold true for physicians directly treating patients, but also holds true for all
involved in medical research, biomedical publication, and
medical education. When integrity in medical science or practice is impugned or threatened—such as by the influence
of industry—patients, clinicians, and researchers are all at
risk for harm, and public trust in research is jeopardized.
Ensuring, maintaining, and strengthening the integrity of
medical science must be a priority for everyone.
Financial Disclosures: None reported.
REFERENCES
1. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from
rofecoxib litigation. JAMA. 2008;299(15):1800-1812.
2. Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for
Alzheimer disease or cognitive impairment: a case study based on documents from
rofecoxib litigation. JAMA. 2008;299(15):1813-1817.
3. DeAngelis C. Rainbow to dark clouds. JAMA. 2005;294:1107.
4. Wazana A. Physicians and the pharmaceutical industry. JAMA. 2000;283
(3):373-380.
5. Steinbrook R. Financial support of continuing medical education. JAMA. 2008;
299(9):1060-1062.
6. Fletcher SW. Chairman’s Summary of the Conference: Continuing Education
in the Health Professions: Improving Healthcare Through Lifelong Learning. New
York, NY: Josiah Macy Jr Foundation; 2008.
7. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA. 2002;287(5):
612-617.
8. Carlat D. Dr drug rep. New York Times Magazine. November 25, 2007.
9. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid
arthritis. JAMA. 2000;284(10):1247-1255.
10. Solomon DH, Avorn J. Coxibs, science, and the public trust. Arch Intern Med.
2005;165(2):158-160.
11. Steinman MA, Bero LA, Chren MM, Landefeld CS. Narrative review: the promotion of gabapentin. Ann Intern Med. 2006;145(4):284-293.
12. Healy D, Cattel D. Interface between authorship, industry and science in the
domain of therapeutics. Br J Psychiatry. 2003;183:22-27.
13. Geba GP, Weaver AL, Polis AB, et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee. JAMA. 2002;287(1):64-71.
14. Scientific Therapeutics Information Inc Web site. http://www.stimedinfo.com
/sti.htm. Accessibility verified March 21, 2008.
15. International Committee of Medical Journal Editors. Uniform requirements for
manuscripts submitted to biomedical journals. http://www.icmje.org. Accessibility verified March 21, 2008.
16. Rennie D, Flanagin A. Authorship! authorship! guests, ghosts, grafters, and
the two-sided coin. JAMA. 1994;271(6):469-471.
17. DeAngelis CD, Drazen JM, Frizelle FA, et al. Clinical trial registration. JAMA.
2004;292(11):1363-1364.
18. Curfman GD, Morrisey S, Drazen JM. Expression of concern: Bombardier et
al., “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in
patients with rheumatoid arthritis,” N Engl J Med 2000;343:1520-8. N Engl J Med.
2005;353(26):2813-2814.
19. DeAngelis CD, Fontanarosa PB, Flanagin A. Reporting financial conflicts of
interest and relationships between investigators and research sponsors. JAMA. 2001;
286(1):89-91.
20. Fontanarosa PB, Flanagin A, DeAngelis CD. Reporting conflicts of interest, financial aspects of research, and role of sponsors in funded studies. JAMA. 2005;
294(1):110-111.
21. Vastag B. Reviewer leaked Avandia study to drug firm. Nature. 2008;451
(7178):509.
(Reprinted) JAMA, April 16, 2008—Vol 299, No. 15
Downloaded from www.jama.com on April 15, 2008
1835